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Acute ischemic stroke is a devastating disease that is often complicated by hemorrhagic
transformation. While significant advances have been made over the past two decades
with regard to emergent treatment of AIS, many of the therapeutic options are limited by
an increased risk of hemorrhage. Here, we sought to review the rates of hemorrhagic trans-
formation in the major clinical trials of AIS intervention. Since the reviewed clinical trials
vary significantly in terms of study design, eligibility criteria, stroke severity, and baseline
demographic data, direct comparisons between the various trials is not valid. Nevertheless,
this review is intended to consolidate the pertinent data on hemorrhagic transformation in
order to call attention to any patterns that may warrant further investigation.
Keywords: acute ischemic stroke, hemorrhagic transformation, intracerebral hemorrhage, fibrinolysis, mechani-
cal thrombectomy
INTRODUCTION
Intracerebral hemorrhage (ICH) is the most common and the
least treatable subtype of hemorrhagic stroke (Sudlow and War-
low, 1997; Flaherty et al., 2005; Zahuranec et al., 2006; Broderick
et al., 2007; Feigin et al., 2009; Sacco et al., 2009). Although the
management of ICH is a topic of intense investigation, treatment
options remain limited. Thus, there is a dire need for continued
research into optimal ICH management. In addition, it is critical
that efforts are simultaneously directed toward preventing ICH
before it occurs. This requires a comprehensive understanding
of the underlying etiology and pathophysiology of the disease.
In this context, it is important to distinguish between sponta-
neous (non-lesional) ICH – parenchymal hemorrhage that occurs
in the absence of an underlying lesion – and secondary ICH,
which occurs in the setting of cerebral tumor, vascular malfor-
mation, ischemic injury, or other underlying lesion. A multitude
of risk factors for spontaneous ICH have been identified, includ-
ing but not limited to hypertension, cerebral amyloid angiopathy
(CAA), sympathomimetic drugs, and advanced age (Harrington
et al., 1983; Cosgrove et al., 1985; Hornig et al., 1986; Lowenstein
et al., 1987; Zodpey et al., 2000; Ariesen et al., 2003). Yet, while such
risk factors are overwhelmingly common in the general population
(Vinters and Gilbert, 1983; Hajjar and Kotchen, 2003), only a small
fraction of these patients experiences ICH. In contrast, secondary
ICH is more predictable, particularly in the setting of an under-
lying ischemic injury. Hornig et al. (1986) observed radiographic
evidence of hemorrhage in 43% (28/65) of cases of acute ischemic
stroke (AIS) followed prospectively with serial computed tomog-
raphy (CT) imaging for 4 weeks. Similarly, Okada et al. (1989)
reported a 40.6% (65/160) rate of hemorrhage in a separate cohort
of AIS patients followed prospectively with serial radiographic
imaging. Thus, it is clear that hemorrhagic transformation occurs
in a significant proportion of patients following ischemic brain
injury.
In this review, we will evaluate the relevant literature regarding
hemorrhagic transformation of acute ischemic stroke (AIS). First,
we will provide a brief overview of the pathogenesis and classi-
fication of hemorrhagic transformation. In turn, we will review
the incidence of hemorrhagic transformation in the major clinical
trials of AIS over the past two decades.
PATHOPHYSIOLOGY OF HEMORRHAGIC TRANSFORMATION
Hemorrhagic transformation of acute ischemic stroke is a com-
plex and multifactorial phenomenon. Within seconds to minutes
after the onset of ischemia, there is a reduction in ATP and a sub-
sequent cessation of Na+-K+ ATPase activity (Rossi et al., 2007).
This leads to a variety of cellular and metabolic derangements,
which collectively lead to a disruption of the blood-brain barrier
(BBB) (Warach and Latour, 2004). Furthermore, ischemia results
in a robust inflammatory response (Janardhan and Qureshi, 2004;
Mocco et al., 2006; Komotar et al., 2008), which further disrupts
normal cerebrovascular anatomy and physiology. The resulting
disruption of the BBB along with the impairment of autoregu-
latory capacity of the cerebral vasculature predisposes to blood
extravasation when the ischemic tissue is eventually reperfused
(Khatri et al., 2012). Importantly, it appears that the degree of
anatomical and physiological disruption is highly dependent on
the duration of ischemia (Rossi et al., 2007; Khatri et al., 2012).
CLASSIFICATION OF HEMORRHAGIC TRANSFORMATION
There is a broad spectrum of severity of hemorrhagic transforma-
tion, ranging from subtle petechial hemorrhage within infarcted
tissue to large-volume hematoma extending beyond the borders
of the infarction (Hornig et al., 1986). The term hemorrhagic
infarction (HI) describes heterogeneous hyperdensity occupying
a portion of an ischemic infarct zone on CT-imaging, whereas
parenchymatous hematoma (PH) refers to a more homogeneous,
dense hematoma with mass effect (Pessin et al., 1990; del Zoppo
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et al., 1992). Fiorelli et al. (1999) refined these criteria to include
two subtypes of HI (HI1 and HI2) and two subtypes of PH
(PH1 and PH2), reflecting the broad spectrum of hemorrhagic
transformation (Table 1).
In addition to providing a framework for characterizing hemor-
rhage after AIS, these criteria may be predictive of the time course
as well as the clinical significance of hemorrhagic transformation.
In the study by Hornig et al. (1986) described previously, hem-
orrhages that occurred within the first week after AIS onset were
more likely to take the form of dense hematoma (consistent with
PH2-type hemorrhagic transformation), as opposed to hemor-
rhages occurring at more distant time points after AIS onset, which
were more likely to be HI1, HI2, or PH1. In a post hoc analysis of
the European Cooperative Acute Stroke Study I (ECASS-I) – a
randomized, placebo-controlled phase III clinical trial of recom-
binant tissue plasminogen activator (rtPA) in AIS – PH2-type
hemorrhagic transformation was found to be a significant pre-
dictor of neurological deterioration (OR 32.3; 95% CI 13.4–77.7)
and of 3 month mortality (OR 18.0; 95% CI 8.1–40.1), whereas
HI1, HI2, and PH1 were not associated with either increased mor-
bidity or mortality (Fiorelli et al., 1999). Despite the utility of
this detailed classification system, many studies characterize hem-
orrhagic transformation as simply symptomatic or asymptomatic
(Multicentre Acute Stroke Trial – Italy (MAST-I) Group, 1995; The
National Institute of Neurological Disorders, 1995; The Multicen-
ter Acute Stroke Trial – Europe Study Group, 1996; The NINDS
t-PA Stroke Study Group, 1997).
RATES OF HEMORRHAGIC TRANSFORMATION IN CLINICAL
TRIALS OF AIS
Over the past two decades, a variety of treatment strategies for
AIS have become available. While the potential benefit is unques-
tionable, these treatment options also have inherent risks of their
own. Fibrinolytic agents – including rtPA and prourokinase –
may increase the risk of systemic and intracranial hemorrhage by
nature of their potent fibrinolytic activity. Alternatively, endovas-
cular treatment modalities may result in mechanical damage to
the blood vessel endothelium, thereby increasing hemorrhage
risk. Thus, it is critical to weigh the potential benefits of vessel
Table 1 | Radiographic classification of the spectrum of hemorrhagic









More confluent hyperdensity throughout the
infarct zone; without mass effect
Parenchymal hematoma
type 1 (PH1)
Homogeneous hyperdensity occupying <30%
of the infarct zone; some mass effect
Parenchymal hematoma
type 2 (PH2)
Homogeneous hyperdensity occupying >30%
of the infarct zone; significant mass effect. Or,
any homogenous hyperdensity located beyond
the borders of the infarct zone
recanalization against the added risk of hemorrhage due to the
particular therapy that is used. In the remainder of this manu-
script, we will review the rates of hemorrhagic transformation
in the major clinical trials of AIS (summarized in Table 2). It is
important to emphasize that there is a significant degree of het-
erogeneity between the design and eligibility criteria of each of the
clinical trials that will be discussed. As a result, the relative rates
of hemorrhagic transformation cannot be directly compared, and
any patterns that are identified must be further investigated in
randomized controlled trials.
INTRAVENOUS FIBRINOLYSIS
In 1996, the United States Food and Drug Administration (FDA)
approved intravenous (IV) rtPA for the treatment of AIS. The
most significant concern surrounding the use of IV rtPA is an
increased risk of hemorrhage, which is particularly concerning
given the already significant rate of hemorrhagic transformation
of AIS even in the absence of a potent fibrinolytic agent. Nonethe-
less, the National Institute of Neurological Disorders and Stroke
(NINDS) rtPA Stroke Study demonstrated surprisingly low rates
of both asymptomatic (4.5%) and symptomatic (6.4%) hemor-
rhagic transformation (4.5%) (The National Institute of Neuro-
logical Disorders and Stroke rtPA Stroke Study Group, 1995). The
Safe Implementation of Thrombolysis in Stroke-Monitoring Study
(SITS-MOST), a large observational study of IV rtPA, also demon-
strated a relatively low rate of asymptomatic hemorrhage (9.6%)
with an additional 7.3% of patients experiencing symptomatic
hemorrhage (Wahlgren et al., 2007). On the other hand, the Euro-
pean Cooperative Acute Stroke Study (ECASS)-II and -III trials
(Hacke et al., 1998, 2008) revealed much higher rates of asympto-
matic hemorrhage (39.6 and 27%, respectively), which was more
consistent with what had been reported in the literature in prior
observational studies of AIS (Hornig et al., 1986; Okada et al.,
1989).
One potential explanation for the discrepantly low asympto-
matic hemorrhage rates in NINDS and SITS-MOST as compared
with ECASS-II and ECASS-III is the difference in the time win-
dow during which the fibrinolytic drug was administered. More
specifically, NINDS and SITS-MOST both required that the drug
be administered within 3 h of AIS onset, whereas ECASS-II and
-III evaluated drug treatment at later time points (within 6 h, and
between 3 and 4.5 h, respectively). As described previously, the
duration of ischemia is a critical determinant of the degree of vas-
cular disruption, and so the delayed drug administration in the
ECASS studies may account for the increased rate of hemorrhage.
However, the ATLANTIS Trial (Clark et al., 1999), which also
evaluated drug administration beyond the 3 h window, revealed
hemorrhage rates more in-line with those found in NINDS and
SITS-MOST. Thus, it is likely that the variation in hemorrhage
rates between the different trials is multifactorial – differences in
eligibility criteria and/or in the way hemorrhage was defined in
each of the trials may have contributed to this variation.
Although our intention is to review the rates of hemorrhagic
transformation in the major clinical trials of AIS intervention, it is
also worthwhile to consider the incidence of hemorrhage in clinical
practice with IV rtPA. Graham (2003) performed a meta-analysis
of 15 open-label studies consisting of 2639 patients treated with
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NINDS 312 7–10 days 4.5% (14/312) 6.4% (20/312) N/A 1.5 hp
ECASS-II 409 7 days 39.6% (161/407) 8.8% (36/407) 8.1% (33/407) N/A
ATLANTIS 272 18–30 h 11.4% (31/272) 7.0% (19/272) N/A 4.36 hp
SITS-MOST 6483 22–36 h 9.6% (617/6438) 7.3% (468/6483) 2.9% (184/6352) 2.3 hp
ECASS-III 418 36 h 27% (113/418) 2.4% (10/418) 1.9% (8/418) 3.98 hp
IST-III 1515 7 days N/A 6.9% (104/1515) N/A 4.2 hp
IA FIBRINOLYSIS
PROACT-I 26 90 days 50% (13/26) 15.4% (4/26) 7.7% (2/26) 5.5 hp
PROACT-II 121 7–10 days 68% (73/108) 10% (11/108) N/A 4.5 hp
COMBINED IV/IA APPROACH
EMS 17 7±1 days 11.8% (2/17) 23.5% (4/17) 0.0% (0/17) 2.6 hp/6.3 hq
IMS-I 80 36 h 43% (34/80) 6.3% (5/80) 7.5% (6/80) 1.33 hp/3.53 hq
IMS-II 81 36 h 32.1% (26/81) 9.9% (8/81) 8.6% (7/81) 2.37 hp/N/Aq
IMS-III 434 24±6 h 27.4% (119/434) 6.2% (27/434) 5.8% (25/434) 2.03 h*p/N/Aq
MECHANICALTHROMBECTOMY
Merci
Phase I 28 24 h 42.9% (12/28) 0.0% (0/28) 0.0% (0/28) 6.25 hq
MERCI Trial 141 24 h 27.7 (39/141) 7.8% (11/141) 1.4% (2/141) 6.4 h*q
Multi-MERCI 164 24 h 30.5% (50/164) 9.8% (16/164) 2.4% (4/164) 5.9 h*q
Penumbra
Pivotal Stroke Trial 125 24 h 16.8% (21/125) 11.2% (14/125) 1.6% (2/125) 4.85 hq
POST Trial 157 24 h 13.4% (21/157) 6.4% (10/157) N/A 5.18 hq
Solitaire
Phase I 20 24 h 30% (6/20) 10.0% (2/20) 5.0% (1/20) 6.7 hq
SWIFT Trial 58 24 h 15.5% (9/58) 2.0% (1/58) 0.0% (0/58) 5.54 h*q
Trevo
TREVO 60 N/A N/A N/A N/A 5.03 hq
TREVO-2 88 18–36 h 40.9% (36/88) 4.5% (4/88) 8.0% (7/88) 5.4 h*q
+Expressed as median value, except when marked with an asterisk.
*Expressed as mean (only when relevant median value was not published).
pTime to initiation of IV fibrinolytic therapy.
qTime to clot lysis (or time to procedure termination when clot lysis was not achieved).
Duration of radiographic follow up expressed in hours (h) or days (d). Clinical trial acronyms are elaborated in the manuscript text.
IV rtPA in the non-clinical trial setting; this analysis revealed a
symptomatic hemorrhage rate of 5.2%, in addition to a 6.3%
asymptomatic hemorrhage rate. Each of the included trials con-
formed to the approved 3 h time window for drug administration
and included a broad range of patient demographics and stroke
severities, as encountered in clinical practice.
INTRAARTERIAL FIBRINOLYSIS
The intraarterial (IA) route of fibrinolytic drug delivery pro-
vides direct access to the occluded vessel and thereby may reduce
the dose of fibrinolytic agent that is required. In turn, this may
decrease the risk of hemorrhagic transformation. Alternatively, an
IA approach to drug delivery may in fact increase hemorrhage rates
due to increased exposure of the injured tissue to the fibrinolytic
agent. In other words, the infarct zone is exposed to the full dose of
fibrinolytic drug when administered intraarterially, whereas when
administered intravenously, the extent of drug exposure in the area
of ischemic injury is dependent on the proportion of cardiac out-
put that reaches that particular vascular territory. In PROACT-I
and PROACT-II – phase II and III clinical trials of IA prouroki-
nase – the rates of asymptomatic hemorrhage were 50 and 68%,
respectively, while the rates of symptomatic hemorrhage were 15.4
and 10%, respectively (del Zoppo et al., 1998; Furlan et al., 1999).
In comparison to the rates observed in clinical trials of IV fibrinol-
ysis, IA drug administration appears to be associated with higher
rates of both symptomatic and asymptomatic hemorrhage. This
may be partially due to inevitable delays in treatment that occur
during mobilization of resources for endovascular intervention,
however a multitude of additional factors are likely to contribute
to this discrepancy as well.
It is important to note that this is not an exhaustive review of the
clinical trials that have evaluated IA fibrinolysis for AIS. Certain
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large, well-designed clinical trials – such as MELT Japan (Ogawa
et al., 2007) – were not included due to restrictive inclusion criteria
(i.e., middle cerebral artery occlusions only in the case of MELT)
and/or failure to report asymptomatic hemorrhage rates.
COMBINED INTRAVENOUS AND INTRAARTERIAL APPROACHES
More recently, some specialized stroke centers have adopted a com-
bined IV and IA approach, in which patients are treated with IV fib-
rinolysis during transport to the endovascular suite for further IA
intervention. This approach affords the advantages of direct access
to the occluded vessel without the inherent delay in treatment
associated with an exclusively endovascular intervention. However
this approach also entails increased exposure to fibrinolytic agents
and endovascular manipulation and thus a theoretically increased
risk of hemorrhagic transformation. Combined approached have
been evaluated in a number of clinical trials, including the Emer-
gency Management of Stroke (EMS) Bridging Trial (Lewandowski
et al., 1999), as well as the Interventional Management of Stroke
(IMS)-I, -II, and -III Trials (IMS Study Investigators, 2004; IMS-
II Trial Investigators, 2007; Broderick et al., 2013). The rates of
asymptomatic hemorrhage in EMS, IMS-I, IMS-II and IMS-III
were 11.8, 43, 32.1, and 27.4%, respectively, whereas symptomatic
hemorrhagic transformation occurred in 23.5, 6.3, 9.9, and 6.2%,
respectively.
Although the rate of asymptomatic hemorrhage was compar-
atively low in EMS, this was compensated for by an anomalously
high rate of symptomatic hemorrhage. Interestingly, the rate of
symptomatic hemorrhage in the combined IV/IA fibrinolysis
group was similar to that in the control group, which received IV
placebo prior to IA fibrinolysis. Thus, the high rate of symptomatic
hemorrhage in this trial may be a reflection of the eligibility criteria
and/or the trial protocol, rather than a reflection of the combined
IV/IA approach. In addition, EMS was a small phase I trial that
was not adequately powered to detect an increased incidence of
hemorrhagic complications, and so generalized conclusions about
the hemorrhage rate with combined IV/IA fibrinolysis should not
be drawn based solely on the results of this trial. On the other
hand, the hemorrhage rates in the IMS trials were lower than
those seen in PROACT studies, thus suggesting that the combined
approach is at least as safe as an exclusively IA approach; however,
it is important to reemphasize that caution must be exercised when
comparing disparate clinical trials with distinct eligibility criteria
and study designs.
MECHANICAL THROMBECTOMY
Mechanical thrombectomy is an endovascular approach to AIS
treatment that attempts to remove the occluding thromboembo-
lus en bloc from the blood vessel. One theoretic advantage of
mechanical thrombectomy is that it may allow for a reduction in
the required dose of fibrinolytic, or perhaps may even eliminate
the need for fibrinolysis altogether. In other words, mechanical
thrombectomy may be used as an alternative to fibrinolytic treat-
ment, or as an adjunct to fibrinolysis in order to achieve higher
rates of recanalization than either treatment strategy alone.
The Merci Retriever (Concentric Medical, Mountain View,
CA, USA) was the first mechanical thrombectomy device that
received FDA-approval for use in AIS patients. In the phase I trial
of this device (Gobin et al., 2004), asymptomatic hemorrhagic
transformation occurred in 42.9% (12/28) of these patients, but
there were no cases of symptomatic hemorrhage. In the simi-
larly designed phase II trial (Smith et al., 2005), 141 patients
were treated with the Merci Retriever. Amongst these patients,
the rates of asymptomatic and symptomatic hemorrhagic trans-
formation were 27.7 and 7.8%, respectively. While it is noteworthy
that there were zero cases of symptomatic hemorrhage in the
phase I trial, the phase II trial revealed a similar rate of symp-
tomatic hemorrhage as had been seen in prior trials of fibrinolytic
agents, thus suggesting that the results of the phase I trial may
be attributable to the small sample size. A separate prospective
trial of the Merci Retriever (Smith et al., 2008), which included
patients with refractory vessel occlusion following IV rtPA admin-
istration, demonstrated comparable rates of both asymptomatic
and symptomatic hemorrhagic transformation (30.5 and 9.8%,
respectively), thus suggesting that prior administration of IV rtPA
does not significantly increase the hemorrhage risk associated with
the use of the Merci device.
The next endovascular device to receive FDA-approval for use
in AIS patients was the Penumbra Thromboaspiration System
(Penumbra,Alameda, CA, USA). The FDA’s approval of this device
was largely based on the results of the Penumbra Pivotal Stroke
Trial (Penumbra Pivotal Stroke Trial Investigators, 2009), which
revealed significantly higher rates of vessel recanalization than
any previously evaluated treatment for AIS, with a comparatively
low rate of asymptomatic hemorrhagic transformation (16.8%)
and a comparable rate of symptomatic hemorrhage (11.2%), rel-
ative to the trials of the Merci Retriever or fibrinolytic agents.
Importantly, statistical analysis revealed that adjunctive use of fib-
rinolytic therapy (either IV or IA) was not a significant predictor
of hemorrhagic transformation in this study. The POST Trial (Tarr
et al., 2010) – a phase IV post-marketing surveillance study of the
Penumbra device – confirmed the low rates of both asymptomatic
and symptomatic hemorrhage (13.4 and 6.4%, respectively).
One of the newest classes of mechanical thrombectomy
devices – reversible stents, or stent retrievers – has come into favor
as a result of high rates of vessel recanalization. There are two
FDA-approved stent retrievers for use in AIS patients: the Soli-
taire Flow Restoration Device (ev3, Plymouth, MN, USA) and the
Trevo Retriever (Concentric Medical, Mountain View, CA, USA).
Twenty patients were enrolled in the phase I trial of the Solitaire
device (Castaño et al., 2010), of which 30% were found to have
asymptomatic hemorrhagic transformation and 10% had symp-
tomatic hemorrhage. In the subsequently performed SWIFT Trial
(Saver et al., 2010), a randomized, parallel-group non-inferiority
study comparing the Solitaire Flow Restoration Device to the Merci
Retriever, 58 patients were treated with the Solitaire device, with
only one patient (2.0%) experiencing symptomatic hemorrhagic
transformation,and an additional 15.5% with asymptomatic hem-
orrhage. The SWIFT Trialists attribute these low hemorrhage
rates to the mechanical superiority of the Solitaire device; more
specifically, they posit that the Solitaire device exerts less radial
pressure on the blood vessel as compared with other mechanical
thrombectomy devices, thereby minimizing injury to the vessel
endothelium. Nonetheless, while the hemorrhage rates within the
Solitaire group of the SWIFT Trial were numerically lower than the
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equivalent rates in the Merci comparison group, this difference was
not statistically significant (difference−9.2%; 95% CI−27.0–9.6;
p-value 0.057).
The TREVO study was a phase II clinical trial of the Trevo
Retriever in AIS patients. The results of this trial, which were
presented at the 2012 International Stroke Conference in New
Orleans, Louisiana (Wahlgren et al., 2012), demonstrated a high
rate of vessel recanalization, but unfortunately the rate of hem-
orrhagic transformation was not reported. TREVO-2 (Nogueira
et al., 2012) was a randomized, parallel-group phase III clinical
trial that directly compared the Trevo device to the Merci Retriever.
Of the 88 patients enrolled into the Trevo arm, 4.5% experienced
symptomatic hemorrhagic transformation, while asymptomatic
hemorrhage occurred in an additional 40.9%.
DISCUSSION
Acute ischemic stroke is associated with significant morbidity and
mortality, and unfortunately this disease is often followed by sub-
sequent hemorrhagic transformation, which may further compli-
cate an already devastating clinical condition. While tremendous
advances have been made with regard to emergent AIS manage-
ment, an increased risk of hemorrhage remains an important
limitation of many of the available therapeutic options. In this
manuscript, we sought to review the rates of hemorrhagic trans-
formation in the major clinical trials of AIS interventions. As
mentioned previously, direct comparison of hemorrhage rates
between the different trials is misleading; differences in clinical
trial design, eligibility criteria, baseline stroke severity, and patient
demographics all have the potential to confound such an analysis.
Thus, the intention of this review is not to draw any definitive
conclusions regarding the relative risk of hemorrhage with any
particular treatment strategy or device, but rather to integrate the
relevant data from multiple trials in order to call attention to any
trends that may warrant further investigation.
We observed a trend toward increased hemorrhage rates as
the time between stroke onset and vessel recanalization increases.
More specifically, the lowest rates of hemorrhagic transforma-
tion were observed in trials of IV fibrinolytic agents, particularly
when the drug was administered within 3 h of AIS onset. Mean-
while, hemorrhage rates were higher when the initial treatment
approach was IA, which inevitably involved delays as the resources
necessary for an endovascular intervention were mobilized. There
are a number of potential explanations for this observation. It
is possible that the increased time lapse prior to blood vessel
recanalization may have a direct effect on rates of hemorrhagic
transformation. In support of this hypothesis is the fact that studies
that allowed for IV fibrinolytic administration beyond 3 h after
symptom onset tended to result in higher rates of hemorrhagic
transformation, as compared with IV fibrinolysis studies in which
drug was administered within the 3 h window. Furthermore, this
hypothesis is also consistent with the underlying pathophysiol-
ogy of ischemic cerebrovascular injury: as described previously,
inflammatory processes are initiated within seconds of the onset of
ischemia, and this inflammation leads to a progressive disruption
of the BBB. Therefore, as the amount of time until recanaliza-
tion increases, the disruption of the BBB becomes more extensive,
and concurrently the risk of hemorrhagic transformation becomes
more significant. Another potential explanation is that endovas-
cular interventions may be intrinsically associated with higher
hemorrhage rates, perhaps as a result of mechanical manipulation
of the blood vessels.
On the other hand, it is possible that confounding variables may
be largely responsible for the trends observed in this review. As dis-
cussed above, these clinical trials vary significantly with regard to
eligibility criteria, patient demographics, baseline stroke severity,
and study design. Furthermore, the clinical trials discussed here
were completed over a span of more than two decades. During
that time period, there have been significant advances in many
aspects of stroke management, including emergency response pro-
tocols, neurocritical care, and imaging technology. The fact that
the more recently performed trials of endovascular thrombectomy
have revealed significantly higher rates of asymptomatic hemor-
rhage (while symptomatic hemorrhage rates have remained fairly
constant) supports the hypothesis that improved imaging technol-
ogy may allow for the identification of subclinical hemorrhages
that were simply not able to be identified in earlier trials of IV fib-
rinolysis. Thus, randomized controlled trials controlling for these
confounding factors are imperative in order to evaluate the relative
risk of hemorrhagic transformation with each of the available AIS
treatment modalities.
In summary, this review of hemorrhagic transformation in
the major clinical trials of AIS intervention demonstrates observ-
able trends toward increasing hemorrhage rates with endovascular
interventions, as well as with increased time lapses between stroke
onset and vessel recanalization; randomized controlled trials are
warranted to verify these observations. In addition, further inves-
tigation is necessary in order to identify other risk factors and
precipitants for hemorrhagic transformation in the setting of AIS.
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